{"id":"NCT02272777","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase","officialTitle":"An Open-label Multi-center Study of Imatinib and Nilotinib in CAMN107ECN02 On-treatment Patients With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase After the End of CAMN107ECN02 Core Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-17","primaryCompletion":"2017-01-30","completion":"2017-01-30","firstPosted":"2014-10-23","resultsPosted":"2019-08-19","lastUpdate":"2019-08-19"},"enrollment":225,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia"],"interventions":[{"type":"DRUG","name":"Imatinib","otherNames":["STI571, Gleevec/Glivec"]},{"type":"DRUG","name":"Nilotinib","otherNames":["AMN107, Tasigna"]}],"arms":[{"label":"Imatinib","type":"ACTIVE_COMPARATOR"},{"label":"Nilotinib","type":"EXPERIMENTAL"}],"summary":"The extension study followed the core study CAMN107ECN02 (NCT01275196). which is an open-label, two armed study. All patients enrolled in this extension study were able to benefit from the treatment given in CAMN107ECN02 per investigator's evaluation. Therefore, in this extension study patient continued treatment of the drug (imatinib or nilotinib) which they were taking at the end of CAMN107ECN02. Treatment arms in CAMN107ECN02 were retained. As long as EC approval and agreement from investigators were obtained, the selected sites for CAMN107ECN02 were applied in this extension study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"From first dose of study treatment to 30 days after last dose of study treatment, up to 31 months","effectByArm":[{"arm":"Imatinib","deltaMin":82,"sd":null},{"arm":"Nilotinib","deltaMin":84,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":112},"commonTop":["Blood triglycerides increased","Blood bilirubin increased","Asthenia","Memory impairment","Blood glucose increased"]}}